KPV for Skin: What the Research Shows on Inflammation, Wounds and Topical Use

KPV for skin is an early research topic, not an established treatment. The KPV peptide, a three-amino-acid fragment of alpha-MSH, is studied in cell cultures, lab skin models and animal wound models for how it may calm inflammatory signalling. KPV is not FDA-approved, and no controlled human trials of KPV for skin have been published.

Searches for KPV for skin have climbed as the peptide appears on serum labels and forums. This guide covers what the research tested, topical versus systemic use, and where the evidence stops.

Also searched as: kpv skin, peptide kpv for skin, kpv peptides for skin, and kpv topical.

Why researchers look at KPV for skin

KPV is the tripeptide lysine, proline, valine. It is the C-terminal end (residues 11 to 13) of alpha-melanocyte-stimulating hormone, or alpha-MSH. Skin makes alpha-MSH, and many skin cells carry its receptor, MC1R.

Alpha-MSH has a long research history as an anti-inflammatory signal. In animal models it reduced inflammation in irritant and allergic contact dermatitis and in cutaneous vasculitis (Brzoska et al., 2008, Endocrine Reviews). The catch is that alpha-MSH also drives pigment, which limits its use.

That is where the KPV peptide comes in. The same review describes KPV as keeping the anti-inflammatory effect of alpha-MSH while lacking its pigmentary action. A later chapter by the same Münster group notes that KPV lacks the sequence motif needed to bind known melanocortin receptors, and that its exact signalling mechanism is still unknown (Brzoska et al., 2010). If you want the broader background first, our KPV anti-inflammatory research overview covers it, and the planned explainer on what the KPV peptide is starts from zero.

What the KPV skin research actually tested

Most KPV skin work happens in a dish. A result in a cell line is a starting point, not a clinical finding.

Keratinocyte and lab skin studies on KPV for skin

Keratinocytes are the main cells of the outer skin layer. A 2025 study exposed human HaCaT keratinocytes to fine dust particles (PM10). Adding KPV restored cell viability, lowered reactive oxygen species and reduced IL-1 beta release, with effects traced to the MAPK and NF-kB pathways. KPV also reduced inflammatory cell death in a three-dimensional lab skin model (Sung et al., 2025, Tissue and Cell).

An earlier study looked at how KPV signals in keratinocytes. It found no rise in cyclic AMP, the classic alpha-MSH messenger, but did see rapid calcium signals under specific lab conditions (Elliott et al., 2004, Journal of Investigative Dermatology). How KPV for skin might work at the receptor level is still unsettled.

Antimicrobial activity

In lab tests, alpha-MSH and KPV inhibited Staphylococcus aureus colony formation and reduced the viability of the yeast Candida albicans (Cutuli et al., 2000, Journal of Leukocyte Biology). Both matter in skin and wound infections.

KPV wound healing research in animal models

KPV wound healing studies are almost all animal work, usually with KPV built into a dressing or gel. Here is a map of the main ones.

What they reported:

• In diabetic mice, the KPV and EGF film improved wound closure, with changes in inflammation, new blood vessel growth and collagen deposition. KPV was paired with a growth factor, so its effect alone cannot be separated out.
• In rats, the KPV hydrogel lowered IL-1 beta and TNF-alpha, raised IL-10 and showed antibacterial activity in MRSA-infected gum ulcers.
• In rabbits, KPV eye drops sped up corneal surface closure compared with saline, an effect blocked by a nitric oxide inhibitor.

Dermatology researchers have argued that truncated alpha-MSH peptides such as KPV are promising candidates for skin wounds and ulcers, while laying out the arguments for and against (Böhm and Luger, 2019, Experimental Dermatology). A 2025 review of tripeptides in wound care lists KPV-loaded hydrogels alongside GHK-based formulations (Adnan et al., 2025). Our planned comparison of KPV vs GHK-Cu explains how those two tripeptides differ.

KPV for skin: psoriasis, eczema and other conditions

A PubMed search for KPV psoriasis studies returned no results when we checked in October 2026. Reviews name inflammatory skin disease as a future target, which is a hypothesis, not a tested use.

The same applies to eczema, acne and rosacea: KPV for skin is marketed for all three, with no published controlled human trial behind any of them. Our seven KPV research findings piece covers what has been tested across all body systems.

KPV topical vs systemic: what is the difference?

When people ask about KPV topical use, they usually mean a cream or serum applied to the skin. Systemic means it enters the bloodstream, such as by injection or by mouth.

• Skin penetration is a real barrier. In human skin samples in the lab, KPV applied passively did not cross the skin at detectable levels. Microneedles increased delivery, and microneedles plus a small electrical current (iontophoresis) increased it further (Pawar et al., 2017, Journal of Pharmaceutical Sciences).
• Carriers change the picture. Many KPV skin studies use hydrogels, films or liposomes to hold the peptide in place. One mouse study used KPV as a targeting tag on liposomes carrying other drugs (Sun et al., 2021, ACS Nano). That is not the same as KPV acting alone.
• Systemic work is mostly gut research. The oral studies, including uptake through the PepT1 transporter, were done in mouse colitis models. Our KPV gut health research guide covers them, and the planned oral KPV vs injection guide compares forms.

So a cream labelled KPV for skin has not shown that it reaches the right layer in people, or that it does anything once there. With a KPV prescription through telos rx, your provider sets the dose, form and schedule, and telos rx makes no claim about which form suits skin.

What is not known about KPV for skin in humans

The gaps matter as much as the findings:

1. No human efficacy trials. We found no published controlled human trials of KPV for any skin condition.
2. No human exposure data, per FDA. FDA's compounding safety page states it has not identified any human exposure data on drug products containing KPV by any route (FDA).
3. No established dose. Online dosing charts for KPV skin use are not evidence-based. See the planned guide on how providers dose KPV.
4. No timeline. There is no evidence-based timeline for skin changes, and telos rx does not promise one.
5. Unclear long-term safety. Side effects in people are poorly documented. The planned KPV side effects guide covers what is reported.

Legal status and the grey market

KPV is not FDA-approved for any use. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against and 1 abstaining to recommend adding KPV to the bulk substances list for compounding. FDA's own briefing documents had recommended against. The vote is advisory and non-binding, pending FDA rulemaking. On October 28, 2026, HHS announced a temporary enforcement discretion policy that covers single-ingredient topical and oral KPV compounded by state-licensed pharmacies with a valid prescription, under strict sourcing, testing and reporting conditions; injectable KPV is not covered (Federal Register notice). It is not FDA approval, and HHS can revisit it. Our PCAC vote explainer and the planned guide on whether KPV is FDA-approved go deeper.

Many KPV creams, serums and vials sold online carry a "research use only" label. Their identity, purity and sterility are unverified. Our guide on how to read a peptide COA explains what paperwork can and cannot tell you. If you compete in tested sport, KPV is not named on the WADA list as far as we know, but non-approved substances fall under section S0, so check the current WADA list and your federation.

How people access KPV with a prescription

1. Online intake. You answer questions about your health, medications and goals.
2. Asynchronous provider review. A US-licensed provider reviews your answers, with no scheduled appointment. A prescription is required, and approval is not guaranteed.
3. Licensed pharmacy. If approved, a licensed US pharmacy compounds KPV. Your provider sets the dose, form and schedule.

Full details are on the KPV page.

Summary: KPV for skin at a glance

KPV for skin is an interesting research thread. Lab and animal work suggests the KPV peptide may calm inflammatory signalling in keratinocytes, has antimicrobial activity in the lab, and has been tested in animal wound models, usually inside a dressing or gel. But there are no published human trials or KPV psoriasis studies, and passive topical delivery looks poor. KPV is not FDA-approved, so a licensed provider is the safest place to start.

KPV for skin FAQ

Does research support KPV for skin?

Research on KPV for skin is limited to cell cultures, lab skin models and animal studies. In those settings, KPV is studied for calming inflammatory signals in keratinocytes and for wound models in mice, rats and rabbits. No published controlled human trials of KPV for skin conditions were found.

Is there research on KPV for psoriasis?

We found no published studies testing KPV in psoriasis. Reviews from dermatology researchers describe KPV as a candidate for inflammatory skin disease in general, based on related alpha-MSH work in dermatitis models. KPV psoriasis claims online go beyond the evidence.

Does topical KPV get through the skin?

In a lab study using human skin samples, KPV applied alone did not pass through the skin at detectable levels. Microneedles and a small electrical current increased delivery. Topical KPV in creams has not been tested for absorption or effect in people.

What does the KPV wound healing research show?

KPV wound healing studies are animal work. A KPV and growth factor film was tested on wounds in diabetic mice, a KPV hydrogel was tested on mouth ulcers in rats, and KPV eye drops were tested on scratched corneas in rabbits. None show effects in people.

Is KPV for skin the same as alpha-MSH?

No. KPV is the last three amino acids of alpha-MSH. Researchers study KPV for skin because it appears to keep much of the anti-inflammatory activity of alpha-MSH in lab work without the tanning or pigment effect of the full hormone.

Is KPV FDA-approved for skin conditions?

No. KPV is not FDA-approved for any use, including skin conditions. In July 2026 an FDA advisory committee voted to recommend adding KPV to the list of bulk substances for compounding, but that vote is non-binding and FDA rulemaking is still pending. A temporary HHS enforcement discretion policy announced October 28, 2026 covers topical and oral KPV compounded under strict conditions, which is also not FDA approval.

How can I get KPV with a prescription?

At telos rx you complete an online intake that a US-licensed provider reviews asynchronously. If appropriate, a licensed US pharmacy compounds KPV and your provider sets the dose, form and schedule. It is subject to medical approval by a licensed provider, and approval is not guaranteed.

This article is for general education and is not medical advice. KPV is not FDA-approved for any use, and compounded KPV has not been evaluated by the FDA for safety, effectiveness or quality. All prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual experiences vary. telos rx is an online-first, asynchronous telehealth service, and medications are compounded by a licensed US pharmacy. Tested athletes should check the current WADA Prohibited List.